SCHEMBL2110195

SCHEMBL2110195

c1cc(OC2CCNC2)ccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.66
CHRNA4 P43681 2/20 0.66
PRKCZ Q05513 1/20 0.63
ROCK1 Q13464 2/20 0.61
CHUK O15111 1/20 0.61
DYRK3 O43781 1/20 0.61
ROCK2 O75116 1/20 0.61
MAP4K4 O95819 1/20 0.61
PIM1 P11309 1/20 0.61
PRKACA P17612 1/20 0.61
RPS6KB1 P23443 1/20 0.61
AKT1 P31749 1/20 0.61
CLK2 P49760 1/20 0.61
PRKX P51817 1/20 0.61
PRKG2 Q13237 1/20 0.61
DYRK1A Q13627 1/20 0.61
PRKG1 Q13976 1/20 0.61
PKN2 Q16513 1/20 0.61
CLK4 Q9HAZ1 1/20 0.61
HRH1 P35367 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264511 1.00 CHRNB2 (0.66) CHRNB2CHRNA4PRKCZROCK1CHUK
SCHEMBL2266554 1.00 CHRNB2 (0.66) CHRNB2CHRNA4PRKCZROCK1CHUK
SCHEMBL26668743 0.89 CHRNB2 (0.68) CHRNB2CHRNA4PRKCZROCK1CHUK
SCHEMBL26668737 0.89 CHRNB2 (0.68) CHRNB2CHRNA4PRKCZROCK1CHUK
SCHEMBL7790143 0.89 CHRNB2 (0.68) CHRNB2CHRNA4PRKCZROCK1CHUK
SCHEMBL187501 0.89 HRH1 (0.66) CHRNB2CHRNA4PRKCZROCK1CHUK
Hydrochloric Acid SCHEMBL15650400 0.88 CHRNB2 (0.66) CHRNB2CHRNA4PRKCZROCK1CHUK
Hydrochloric Acid SCHEMBL26599814 0.88 CHRNB2 (0.66) CHRNB2CHRNA4PRKCZROCK1CHUK
Hydrochloric Acid SCHEMBL26599582 0.88 CHRNB2 (0.66) CHRNB2CHRNA4PRKCZROCK1CHUK
Hydrochloric Acid SCHEMBL26599588 0.88 CHRNB2 (0.66) CHRNB2CHRNA4PRKCZROCK1CHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
WO-2024009215-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-11 WO disclosed
WO-2021077010-A1 BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY ARVINAS OPERATIONS, INC. (US) 2021-04-22 WO disclosed
EP-2857388-A1 Azoles containing sulfone Grünenthal GmbH (DE) 2015-04-08 EP disclosed
EP-2403854-B1 SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS GRUENENTHAL GMBH (DE) 2013-09-11 EP disclosed
EP-2403854-B1 SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS GRUENENTHAL GMBH (DE) 2013-09-11 EP disclosed
US-8158628-B2 Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals GRUENENTHAL GMBH (DE) 2012-04-17 US disclosed
US-8158628-B2 Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals GRUENENTHAL GMBH (DE) 2012-04-17 US disclosed
US-8158628-B2 Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals GRUENENTHAL GMBH (DE) 2012-04-17 US disclosed
US-20100234387-A1 Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals GRUENETHAL GMBH (DE) 2010-09-16 US disclosed
US-20100234387-A1 Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals GRUENETHAL GMBH (DE) 2010-09-16 US disclosed
US-20100234387-A1 Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals GRUENETHAL GMBH (DE) 2010-09-16 US disclosed
WO-2010099938-A1 SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS Grünenthal GmbH (DE) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234387-A1 Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals BDKRB1, BDKRB2, KCNB1 CHRNB2 870/4885CHRNA4 1063/4885PRKCZ 1651/4885
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CHRNB2 3816/4885CHRNA4 4788/4885PRKCZ 3986/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CHRNB2 3816/4885CHRNA4 4788/4885PRKCZ 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.